196 related articles for article (PubMed ID: 34233924)
41. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
[TBL] [Abstract][Full Text] [Related]
42. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
43. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
44. LMNA knock-down affects differentiation and progression of human neuroblastoma cells.
Maresca G; Natoli M; Nardella M; Arisi I; Trisciuoglio D; Desideri M; Brandi R; D'Aguanno S; Nicotra MR; D'Onofrio M; Urbani A; Natali PG; Del Bufalo D; Felsani A; D'Agnano I
PLoS One; 2012; 7(9):e45513. PubMed ID: 23049808
[TBL] [Abstract][Full Text] [Related]
45. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
[TBL] [Abstract][Full Text] [Related]
46. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
47. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
48. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL
PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278
[TBL] [Abstract][Full Text] [Related]
49. SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation.
Xiang Y; Fang B; Liu Y; Yan S; Cao D; Mei H; Wang Q; Hu Y; Guo T
Life Sci; 2020 Sep; 256():117971. PubMed ID: 32553925
[TBL] [Abstract][Full Text] [Related]
50. Treatment of a chemoresistant neuroblastoma cell line with the antimalarial ozonide OZ513.
Coulter DW; McGuire TR; Sharp JG; McIntyre EM; Dong Y; Wang X; Gray S; Alexander GR; Chatuverdi NK; Joshi SS; Chen X; Vennerstrom JL
BMC Cancer; 2016 Nov; 16(1):867. PubMed ID: 27821095
[TBL] [Abstract][Full Text] [Related]
51. Global transcription analysis of Krebs tricarboxylic acid cycle mutants reveals an alternating pattern of gene expression and effects on hypoxic and oxidative genes.
McCammon MT; Epstein CB; Przybyla-Zawislak B; McAlister-Henn L; Butow RA
Mol Biol Cell; 2003 Mar; 14(3):958-72. PubMed ID: 12631716
[TBL] [Abstract][Full Text] [Related]
52. RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model.
Byrne FL; Yang L; Phillips PA; Hansford LM; Fletcher JI; Ormandy CJ; McCarroll JA; Kavallaris M
Oncogene; 2014 Feb; 33(7):882-90. PubMed ID: 23396365
[TBL] [Abstract][Full Text] [Related]
53. Direct Targeting of
Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
[TBL] [Abstract][Full Text] [Related]
54. Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation.
Zhang X; Dong Z; Zhang C; Ung CY; He S; Tao T; Oliveira AM; Meves A; Ji B; Look AT; Li H; Neel BG; Zhu S
Cell Rep; 2017 Mar; 18(12):2932-2942. PubMed ID: 28329685
[TBL] [Abstract][Full Text] [Related]
55. Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.
Carter DR; Sutton SK; Pajic M; Murray J; Sekyere EO; Fletcher J; Beckers A; De Preter K; Speleman F; George RE; Haber M; Norris MD; Cheung BB; Marshall GM
Mol Oncol; 2016 Jun; 10(6):866-78. PubMed ID: 26996379
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma.
Ren Y; Chan HM; Fan J; Xie Y; Chen YX; Li W; Jiang GP; Liu Q; Meinhardt A; Tam PK
Oncogene; 2006 Jun; 25(25):3501-8. PubMed ID: 16449971
[TBL] [Abstract][Full Text] [Related]
57. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
58. Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface.
Koach J; Holien JK; Massudi H; Carter DR; Ciampa OC; Herath M; Lim T; Seneviratne JA; Milazzo G; Murray JE; McCarroll JA; Liu B; Mayoh C; Keenan B; Stevenson BW; Gorman MA; Bell JL; Doughty L; Hüttelmaier S; Oberthuer A; Fischer M; Gifford AJ; Liu T; Zhang X; Zhu S; Gustafson WC; Haber M; Norris MD; Fletcher JI; Perini G; Parker MW; Cheung BB; Marshall GM
Cancer Res; 2019 Nov; 79(21):5652-5667. PubMed ID: 31501192
[TBL] [Abstract][Full Text] [Related]
59. Collaborative ISL1/GATA3 interaction in controlling neuroblastoma oncogenic pathways overlapping with but distinct from MYCN.
Zhang Q; Zhang Q; Jiang X; Ye Y; Liao H; Zhu F; Yan J; Luo L; Tian L; Jiang C; Chen Y; Liang X; Sun Y
Theranostics; 2019; 9(4):986-1000. PubMed ID: 30867811
[No Abstract] [Full Text] [Related]
60. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
